Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 18/20 | 0.84 |
| ▸ | NOTCH3 | Q9UM47 | 17/20 | 0.84 |
| ▸ | NOTCH2 | Q04721 | 1/20 | 0.84 |
| ▸ | NOTCH4 | Q99466 | 1/20 | 0.84 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.73 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.73 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.73 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.73 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.73 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.73 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.73 |
| ▸ | CCKBR | P32239 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osugacestat SCHEMBL29412689 | 1.00 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 | |
| Osugacestat SCHEMBL15622455 | 1.00 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 | |
| Osugacestat SCHEMBL12543868 | 1.00 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 | |
| Osugacestat SCHEMBL17420836 | 1.00 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 | |
| Osugacestat SCHEMBL12543867 | 1.00 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 | |
| Osugacestat SCHEMBL18288911 | 1.00 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 | |
| SCHEMBL22970147 | 0.97 | NOTCH1 (0.80) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 | |
| SCHEMBL25901263 | 0.97 | NOTCH1 (0.88) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 | |
| SCHEMBL22660068 | 0.96 | NOTCH1 (0.83) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 | |
| SCHEMBL22660067 | 0.96 | NOTCH1 (0.89) | NOTCH1NOTCH3NOTCH2NOTCH4PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190350961-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350961-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | NOTCH1 501/4885NOTCH3 295/4885NOTCH2 395/4885 |
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | VEGFA, PGF, FLT4 | NOTCH1 501/4885NOTCH3 295/4885NOTCH2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.